홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Memantine Hydrochloride

HCID 181458
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
19982-08-2
표준 SMILES
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
InChIKey
LDDHMLJTFXJGPI-UHFFFAOYSA-N
분자식
C12H22ClN
평균 분자량
215.76 g/mol
단동위원소 질량
215.1440774

개요

Memantine hydrochloride is a hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as an antidepressant, an antiparkinson drug, a dopaminergic agent, a NMDA receptor antagonist and a neuroprotective agent. It contains a memantinium(1+).

이름 및 식별자

우선 이름
Memantine Hydrochloride
IUPAC
3,5-dimethyladamantan-1-amine;hydrochloride
영어명
Memantine
분자식
C12H21N
분자량
179.3

이름 및 동의어

MEMANTINE HYDROCHLORIDE41100-52-1Memantine HCL3,5-dimethyladamantan-1-amine hydrochloride3,5-Dimethyl-1-adamantanamine hydrochlorideAkatinolNamenda XRMemaryMemantine MerzMemantine MylanMemantine AccordMemantine LEK
이름 더 보기
C137361-Amino-3,5-dimethyladamantane(1r,3R,5S,7r)-3,5-dimethyladamantan-1-amineMEMANTINEMemartineAKOS BB-9600AURORA KA-7643Memantine(Base)7-DIMETHYLXANTHINETIMTEC-BB SBB002574
1-Amino-3,5-dimethyladamantane HydrochlorideAcrescentBalaxurAuxuraMemantine ratiopharmJY0WD0UA60SUN-Y7017NSC-102290

데이터베이스 식별자

CAS
19982-08-2、41100-52-1
PubChem CID
181458
DTXSID
DTXSID90961439
ChEMBL
CHEMBL1699

물성

구조 계산 물성

극성 표면적
26 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
1
회전 가능 결합 수
0
무거운 원자 수
14
형식 전하
0
복잡도
240

실험 및 물리화학적 성질

Solubility29.4 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 6건

Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agents; Excitatory Amino Acid Antagonists

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Collision Cross Section145.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
258 °C · 258 °C
끓는 점
239.8 · 239.8±8.0 °C(Predicted)
밀도
1.046 · 1.046
굴절률
25 · nD25 1.4941
저장 조건
2 · Keep in dark place,Inert atmosphere,2-8°C
용해도
클로로포름 (약간 용해됨), DMSO (약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
10.79 · 10.79±0.60(Predicted)
색상
무색 오일에서 회백색 왁스로
BCS Class
1 · 1

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 5% (1 of 20) of reports.

Warning

H302 (80%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 20 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (80%)

독성 정보

TreatmentAs in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine. (L1712)
Exposure RoutesWell absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
Toxicity Summary · 1건

Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg<sup>2+</sup> ions and allow continuous influx of Ca<sup>2+</sup> ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg<sup>2+</sup> ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca<sup>2+</sup> ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT<sub>3</sub>) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for gamma-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane. Route of Elimination: Memantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. It is excreted predominantly in the urine, unchanged. Half Life: 60-100 hours

FDA Pharmacological Classification · 6건

MEMANTINE HYDROCHLORIDE

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MEMANTINE HYDROCHLORIDE ORAL

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MEMANTINE HCL

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MeSH Pharmacological Classification · 3건

Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.

용도 및 제조

UsesFor the treatment of moderate to severe dementia of the Alzheimer's type.
응용 분야 · 2건

역사Memantine was first synthesized, patented, and described by Eli Lilly and Company in 1963 as an anti-diabetic agent, but it was ineffective at lowering blood sugar. By 1972, it was discovered to have central nervous system (CNS) activity, and was developed by Merz for treatment of neurological diseases, such as Parkinson's disease. Memantine was first studied in the treatment of Alzheimer's disease in 1986. The drug was first marketed for dementia in 1989 in Germany under the name Axura. Memantine was approved in the European Union in 2002 and in the United States in 2003.

관련 반응

4건
반응 기록 만들기
HRID 84161 반응식
HRID 84161반응물로
HRID 922821 반응식
HRID 922821반응물로
HRID 1112396 반응식
HRID 1112396생성물로
HRID 1783798 반응식
HRID 1783798반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
ChEBI
CHEBI:64323
UNII
JY0WD0UA60
EC Number
255-219-6
InChI
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
InChIKey
BUGYDGFZZOZRHP-UHFFFAOYSA-N
SMILES
C12(N)CC3(C)CC(CC(C)(C3)C1)C2
Signs and Symptoms · 1건

Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Memantine hydrochloride

vLess-DILI-concern

7

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

hazard_code
Xi
safety_code
24/25
유해 물질 데이터
19982-08-2(Hazardous Substances Data)

용도Recent phase 3 clinical trials have shown that Memantine is an effective way of treatment of both mild and moderate-to-severe Alzheimer''s disease and possibly vascular dementia (multi-infarct dementia). Memantine’s method of action involves an uncompetitive, low-affinity, open-channel blocker; it enters the receptor-associated ion channel preferentially when it is excessively open, and, most importantly, its off-rate is relatively fast so that it does not substantially accumulate in the channel to interfere with normal synaptic transmission.

상·하류 제품 정보

상류 원료

황산수산화나트륨염산아세토나이트릴
추가 설명 · 1건

정의ChEBI: A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.